急性B型主动脉夹层Zone 2 TEVAR术后加权10年生存与神经结局
该单中心回顾性研究纳入2010至2020年因急性B型主动脉夹层行Zone 2胸主动脉腔内修复术的253例患者,采用逆概率治疗加权比较左锁骨下动脉覆盖与血运重建两组。结果显示两组术后II型内漏、植入后综合征、30天死亡率和早期脑血管意外发生率相当,10年脑血管意外发生率与无主要不良心血管事件生存率无显著差异,植入后综合征是脑血管意外的独立预测因子。
要点
- 左锁骨下动脉血运重建不增加围术期及远期并发症风险。
- 两组5年和10年缺血性卒中、脑血管意外、生存及无主要不良心血管事件生存均无统计学差异。
- 植入后综合征是Zone 2 TEVAR术后脑血管意外的独立预测因子(HR 2.65)。
核心结论
- 左锁骨下动脉血运重建不增加围术期或远期并发症风险,两组5年和10年缺血性卒中率、脑血管意外率、生存率及无主要不良心血管事件生存率在统计学上相当,植入后综合征是Zone 2 TEVAR术后脑血管意外的显著危险因素。
研究设计与样本
- 回顾性分析2010至2020年一家中国国家级主动脉中心连续因急性B型主动脉夹层行Zone 2胸主动脉腔内修复术的患者,最终纳入253例,采用逆概率治疗加权平衡左锁骨下动脉覆盖组与血运重建组的基线差异。
主要发现
- 左锁骨下动脉血运重建后,术后II型内漏发生率38.9% vs 38.2%(P = .91),植入后综合征发生率38.0% vs 38.5%(P = .938),30天死亡率0.6% vs 1.1%(P = .568),早期脑血管意外发生率0.6% vs 0.5%(P = .931),两组相当。
- 10年随访时脑血管意外发生率4.8% vs 12.1%(P = .34),无主要不良心血管事件生存率91.2% vs 78.5%(P = .55),两组无显著差异。
- 加权多变量分析显示,胸主动脉腔内修复术后植入后综合征是脑血管意外的独立预测因子(风险比2.65;95%置信区间1.10-6.42;P = .03)。
关键数值与推荐
- 术后II型内漏:38.9% vs 38.2%(P = .91)。
- 植入后综合征:38.0% vs 38.5%(P = .938)。
- 30天死亡率:0.6% vs 1.1%(P = .568)。
- 早期脑血管意外:0.6% vs 0.5%(P = .931)。
- 10年脑血管意外发生率:4.8% vs 12.1%(P = .34);10年无主要不良心血管事件生存率:91.2% vs 78.5%(P = .55)。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The long-term benefits of left subclavian artery (LSA) revascularization during thoracic endovascular aortic repair (TEVAR) for patients with acute type B aortic dissection (aTBAD) remain controversial. This study aimed to evaluate the impact of LSA revascularization during TEVAR on short- and long-term survival and neurologic outcomes in patients with aTBAD. METHODS: We retrospectively analyzed data from consecutive patients with aTBAD undergoing zone 2 TEVAR between 2010 and 2020 at one Chinese national aortic center. Inverse probability of treatment weighting was employed to mitigate baseline differences between LSA coverage and revascularization groups. Long-term survival, freedom from major adverse cardiovascular events (MACE), ischemic stroke rates, and cerebrovascular accident (CVA) rates were assessed using the Kaplan-Meier analysis. Weighted logistic and Cox regression models were applied to identify predictors of short- and long-term outcomes. RESULTS: The final analysis included 253 patients. Intergroup balance was achieved after inverse probability of treatment weighting. After LSA revascularization, incidences of postoperative type II endoleak (38.9% vs 38.2%; P = .91), post implantation syndrome (38.0% vs 38.5%; P = .938), 30-day mortality (0.6% vs 1.1%; P = .568), and early CVA (0.6% vs 0.5%; P = .931) were comparable between groups. There was no significant difference in CVA incidence (4.8% vs 12.1%; P = .34) or freedom from MACE (91.2% vs 78.5%; P = .55) at 10-year follow-up. Weighted multivariable analysis identified post implantation syndrome after TEVAR as an independent predictor of CVA (hazard ratio, 2.65; 95% confidence interval, 1.10-6.42; P = .03). CONCLUSIONS: LSA revascularization during TEVAR does not increase risks for perioperative or long-term morbidities. Ischemic stroke rates, CVA rates, survival, and MACE-free survival were statistically comparable between groups at 5- and 10-year follow-up. Post implantation syndrome emerged as a significant CVA risk factor after zone 2 TEVAR for aTBAD.
引用
- Cao Z, Wu Z, Gao H, et al. Weighted 10-year survival and neurological outcomes after zone 2 thoracic endovascular aortic repair for acute type B aortic dissection. J Vasc Surg. 2025. PMID: 40409433. doi:10.1016/j.jvs.2025.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。